Therapeutic targets: MTOR and related pathways.

Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology (2008) 3.04

The mTOR signalling pathway in human cancer. Int J Mol Sci (2012) 2.38

Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies. Epilepsia (2009) 1.98

Tumor biology and prognostic factors in renal cell carcinoma. Oncologist (2011) 1.62

Molecular pathways: reactive oxygen species homeostasis in cancer cells and implications for cancer therapy. Clin Cancer Res (2013) 1.56

Rapalogs in cancer prevention: anti-aging or anticancer? Cancer Biol Ther (2012) 1.40

eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther (2008) 1.26

Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol (2009) 1.21

Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. J Clin Oncol (2011) 1.18

Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. Jpn J Clin Oncol (2010) 1.18

The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit. Genes Cancer (2010) 1.14

Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis. Neurosci Lett (2011) 1.12

Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab (2012) 1.11

Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem (2009) 1.10

Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging. Aging (Albany NY) (2012) 1.05

Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neurooncol (2009) 1.05

Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin Cancer Res (2011) 1.03

Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. Eur J Pharmacol (2008) 1.03

Targeting mTOR pathway: A new concept in cancer therapy. Indian J Med Paediatr Oncol (2010) 0.99

Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat Rev (2013) 0.98

Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors. J Hematol Oncol (2011) 0.97

Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines. Mol Cancer Ther (2008) 0.96

Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat Rev Rheumatol (2015) 0.96

mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging. Ann N Y Acad Sci (2015) 0.93

Effect of sirolimus on urinary bladder cancer T24 cell line. J Exp Clin Cancer Res (2009) 0.92

A polymorphism (rs2295080) in mTOR promoter region and its association with gastric cancer in a Chinese population. PLoS One (2013) 0.92

Luteinizing hormone stimulates mammalian target of rapamycin signaling in bovine luteal cells via pathways independent of AKT and mitogen-activated protein kinase: modulation of glycogen synthase kinase 3 and AMP-activated protein kinase. Endocrinology (2010) 0.90

Regulation of mTORC1 complex assembly and signaling by GRp58/ERp57. Mol Cell Biol (2011) 0.90

Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma. Br J Cancer (2012) 0.89

New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma. Cancer (2011) 0.85

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas. Br J Cancer (2015) 0.82

Cell cycle progression or translation control is not essential for vesicular stomatitis virus oncolysis of hepatocellular carcinoma. PLoS One (2010) 0.82

The molecular biology of pancreatic cancer. Gastrointest Cancer Res (2007) 0.81

Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer. Womens Health (Lond Engl) (2014) 0.80

The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity. BMC Cancer (2011) 0.79

Pharmacokinetic Evaluation of a DSPE-PEG2000 Micellar Formulation of Ridaforolimus in Rat. Pharmaceutics (2012) 0.79

A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors. Oncotarget (2016) 0.76

Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. Am J Cancer Res (2014) 0.76

Synergistic antitumor activity of rapamycin and EF24 via increasing ROS for the treatment of gastric cancer. Redox Biol (2016) 0.76

Taxanes: their impact on gynecologic malignancy. Anticancer Drugs (2014) 0.75

Artocarpin Induces Apoptosis in Human Cutaneous Squamous Cell Carcinoma HSC-1 Cells and Its Cytotoxic Activity Is Dependent on Protein-Nutrient Concentration. Evid Based Complement Alternat Med (2015) 0.75

Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs. Onco Targets Ther (2012) 0.75

Insights into molecular therapy of glioma: current challenges and next generation blueprint. Acta Pharmacol Sin (2017) 0.75

The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review). Int J Mol Med (2017) 0.75